216 related articles for article (PubMed ID: 27940027)
1. Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.
Chou S
Antiviral Res; 2017 Feb; 138():57-60. PubMed ID: 27940027
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.
Chou S
J Clin Virol; 2011 Apr; 50(4):287-91. PubMed ID: 21295516
[TBL] [Abstract][Full Text] [Related]
3. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet.
Ducancelle A; Champier G; Alain S; Petit F; Le Pors MJ; Mazeron MC
Antivir Ther; 2006; 11(4):537-40. PubMed ID: 16856628
[TBL] [Abstract][Full Text] [Related]
4. Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet.
Gilbert C; Azzi A; Goyette N; Lin SX; Boivin G
Antimicrob Agents Chemother; 2011 Sep; 55(9):4019-27. PubMed ID: 21709106
[TBL] [Abstract][Full Text] [Related]
5. Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
Fischer L; Imrich E; Sampaio KL; Hofmann J; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2016 Jul; 131():1-8. PubMed ID: 27058773
[TBL] [Abstract][Full Text] [Related]
6. Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance.
Chou S; Ercolani RJ; Lanier ER
Antimicrob Agents Chemother; 2016 Jun; 60(6):3845-8. PubMed ID: 27044553
[TBL] [Abstract][Full Text] [Related]
7. Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus.
Chou S; Marousek G; Li S; Weinberg A
J Clin Virol; 2008 Sep; 43(1):107-9. PubMed ID: 18502683
[TBL] [Abstract][Full Text] [Related]
8. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
Chou S; Marousek GI
J Virol; 2008 Jan; 82(1):246-53. PubMed ID: 17942550
[TBL] [Abstract][Full Text] [Related]
9. Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis.
Andouard D; Mazeron MC; Ligat G; Couvreux A; Pouteil-Noble C; Cahen R; Yasdanpanah Y; Deering M; Viget N; Alain S; Hantz S
Antiviral Res; 2016 May; 129():115-119. PubMed ID: 26872863
[TBL] [Abstract][Full Text] [Related]
10. Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility.
Piret J; Goyette N; Eckenroth BE; Drouot E; Götte M; Boivin G
J Virol; 2015 Apr; 89(8):4636-44. PubMed ID: 25673718
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial.
Chou S; Boivin G; Ives J; Elston R
J Infect Dis; 2014 Apr; 209(8):1219-26. PubMed ID: 24273181
[TBL] [Abstract][Full Text] [Related]
12. Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase.
Mousavi-Jazi M; Schloss L; Wahren B; Brytting M
J Clin Virol; 2003 Apr; 26(3):301-6. PubMed ID: 12637079
[TBL] [Abstract][Full Text] [Related]
13. [Mechanism of drug-resistance in human cytomegalovirus].
Eizuru Y
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():476-9. PubMed ID: 17455666
[No Abstract] [Full Text] [Related]
14. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
Chou S; Marousek GI; Van Wechel LC; Li S; Weinberg A
Antimicrob Agents Chemother; 2007 Nov; 51(11):4160-2. PubMed ID: 17709468
[TBL] [Abstract][Full Text] [Related]
15. Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.
Tchesnokov EP; Gilbert C; Boivin G; Götte M
J Virol; 2006 Feb; 80(3):1440-50. PubMed ID: 16415021
[TBL] [Abstract][Full Text] [Related]
16. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS.
Baldanti F; Underwood MR; Stanat SC; Biron KK; Chou S; Sarasini A; Silini E; Gerna G
J Virol; 1996 Mar; 70(3):1390-5. PubMed ID: 8627655
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.
Scott GM; Isaacs MA; Zeng F; Kesson AM; Rawlinson WD
J Med Virol; 2004 Sep; 74(1):85-93. PubMed ID: 15258973
[TBL] [Abstract][Full Text] [Related]
18. Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation.
Fischer L; Laib Sampaio K; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2013 Dec; 100(3):575-7. PubMed ID: 24120366
[TBL] [Abstract][Full Text] [Related]
19. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.
Cihlar T; Fuller MD; Cherrington JM
J Virol; 1998 Jul; 72(7):5927-36. PubMed ID: 9621055
[TBL] [Abstract][Full Text] [Related]
20. Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.
Chou S; Marousek G; Bowlin TL
Antimicrob Agents Chemother; 2012 Jan; 56(1):197-201. PubMed ID: 21968367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
